Dwain Tolbert

848 total citations
36 papers, 660 citations indexed

About

Dwain Tolbert is a scholar working on Psychiatry and Mental health, Pediatrics, Perinatology and Child Health and Pharmacology. According to data from OpenAlex, Dwain Tolbert has authored 36 papers receiving a total of 660 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Psychiatry and Mental health, 17 papers in Pediatrics, Perinatology and Child Health and 12 papers in Pharmacology. Recurrent topics in Dwain Tolbert's work include Epilepsy research and treatment (21 papers), Pharmacological Effects and Toxicity Studies (17 papers) and Drug Transport and Resistance Mechanisms (9 papers). Dwain Tolbert is often cited by papers focused on Epilepsy research and treatment (21 papers), Pharmacological Effects and Toxicity Studies (17 papers) and Drug Transport and Resistance Mechanisms (9 papers). Dwain Tolbert collaborates with scholars based in United States, Denmark and Czechia. Dwain Tolbert's co-authors include Aziz Karim, Charlie Cao, Ihor Bekersky, Mark Walzer, Rajeev Menon, Robert A. Blum, Richard C. Hubbard, Mario Ángel-González, Jocelyn H. Leu and William R. Ravis and has published in prestigious journals such as Neurology, Epilepsia and Clinical Pharmacokinetics.

In The Last Decade

Dwain Tolbert

33 papers receiving 631 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dwain Tolbert United States 13 154 153 135 133 100 36 660
Arzu Gunes Sweden 15 221 1.4× 168 1.1× 119 0.9× 83 0.6× 133 1.3× 23 832
David W. J. Clark New Zealand 17 72 0.5× 163 1.1× 77 0.6× 108 0.8× 199 2.0× 37 944
Karin Kramer Nielsen Denmark 16 130 0.8× 220 1.4× 150 1.1× 105 0.8× 203 2.0× 28 921
Scott R. Hamann United States 16 95 0.6× 125 0.8× 84 0.6× 146 1.1× 207 2.1× 37 929
Jesús Novalbos Spain 17 170 1.1× 125 0.8× 80 0.6× 92 0.7× 162 1.6× 47 795
İhsan Kara Türkiye 18 219 1.4× 61 0.4× 47 0.3× 62 0.5× 161 1.6× 39 845
Pablo Zubiaur Spain 17 171 1.1× 97 0.6× 71 0.5× 164 1.2× 161 1.6× 73 877
Leah M. Hesse United States 17 104 0.7× 137 0.9× 56 0.4× 234 1.8× 242 2.4× 21 1.2k
Allen A. Lai United States 17 206 1.3× 108 0.7× 22 0.2× 197 1.5× 86 0.9× 25 852
P d'Athis France 17 205 1.3× 93 0.6× 73 0.5× 284 2.1× 97 1.0× 48 752

Countries citing papers authored by Dwain Tolbert

Since Specialization
Citations

This map shows the geographic impact of Dwain Tolbert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dwain Tolbert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dwain Tolbert more than expected).

Fields of papers citing papers by Dwain Tolbert

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dwain Tolbert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dwain Tolbert. The network helps show where Dwain Tolbert may publish in the future.

Co-authorship network of co-authors of Dwain Tolbert

This figure shows the co-authorship network connecting the top 25 collaborators of Dwain Tolbert. A scholar is included among the top collaborators of Dwain Tolbert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dwain Tolbert. Dwain Tolbert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Klein, Pavel, Dwain Tolbert, & Barry E. Gidal. (2019). Drug–drug interactions and pharmacodynamics of concomitant clobazam and cannabidiol or stiripentol in refractory seizures. Epilepsy & Behavior. 99. 106459–106459. 28 indexed citations
2.
Tolbert, Dwain, Hui‐May Chu, & Ene Ette. (2019). Pharmacometrics of clobazam in pediatrics: Prediction of effective clobazam doses for Dravet syndrome. Epilepsy Research. 157. 106182–106182. 2 indexed citations
3.
Tolbert, Dwain, Hui‐May Chu, & Ene Ette. (2018). Pharmacometrics of Clobazam in Pediatrics: Population PK Modeling to Predict Effective Clobazam Doses for Dravet Syndrome (P4.265). Neurology. 90(15_supplement). 1 indexed citations
4.
Brodie, Martin J., Pavel Klein, Raman Sankar, Barry E. Gidal, & Dwain Tolbert. (2017). Continuity of Care With IV Carbamazepine: A Case Report for Maintaining Treatment (P5.235). Neurology. 88(16_supplement).
5.
Ravis, William R., Dwain Tolbert, Aziz Karim, & James C. Cloyd. (2017). Pharmacokinetics of IV and Oral Carbamazepine by Renal Function Status (P6.250). Neurology. 88(16_supplement).
6.
Tolbert, Dwain, et al.. (2017). A Thorough QT/QTc Study of Clobazam in Healthy Volunteers. Clinical Therapeutics. 39(10). 2073–2086. 5 indexed citations
7.
Lee, Deborah, et al.. (2015). Clobazam for Dravet Syndrome: Designing a Clinical Study Using Pharmacokinetic/Pharmacodynamic Modeling (P1.260). Neurology. 84(14_supplement). 2 indexed citations
8.
Tolbert, Dwain, Stuart Harris, Ihor Bekersky, Deborah Lee, & Jouko Isojärvi. (2014). Withdrawal-related adverse events from clinical trials of clobazam in Lennox–Gastaut syndrome. Epilepsy & Behavior. 37. 11–15. 13 indexed citations
9.
Nielsen, Jace, et al.. (2014). Population Pharmacokinetics Analysis of Vigabatrin in Adults and Children with Epilepsy and Children with Infantile Spasms. Clinical Pharmacokinetics. 53(11). 1019–1031. 7 indexed citations
10.
Nielsen, Jace, et al.. (2014). Population dose‐response analysis of daily seizure count following vigabatrin therapy in adult and pediatric patients with refractory complex partial seizures. The Journal of Clinical Pharmacology. 55(1). 81–92. 5 indexed citations
11.
Tolbert, Dwain & Ihor Bekersky. (2013). Pharmacokinetics of N -Desmethylclobazam, the Active and Primary Metabolite of Clobazam (P01.042). Neurology. 80(7_supplement). 2 indexed citations
12.
Walzer, Mark, Ihor Bekersky, Stephen Wanaski, et al.. (2011). Oral toxicity of vigabatrin in immature rats: Characterization of intramyelinic edema. NeuroToxicology. 32(6). 963–974. 11 indexed citations
13.
Menon, Rajeev, et al.. (2007). Plasma and urine pharmacokinetics of niacin and its metabolites from an extended-release niacin formulation. International Journal of Clinical Pharmacology and Therapeutics. 45(8). 448–454. 35 indexed citations
14.
Menon, Rajeev, et al.. (2007). Effect of the Rate of Niacin Administration on the Plasma and Urine Pharmacokinetics of Niacin and Its Metabolites. The Journal of Clinical Pharmacology. 47(6). 681–688. 44 indexed citations
15.
16.
Karim, Aziz, Dwain Tolbert, & Charlie Cao. (2006). Disposition Kinetics and Tolerance of Escalating Single Doses of Ramelteon, a High‐Affinity MT1 and MT2 Melatonin Receptor Agonist Indicated for Treatment of Insomnia. The Journal of Clinical Pharmacology. 46(2). 140–148. 105 indexed citations
17.
Ravis, William R., et al.. (2005). Pharmacokinetics of Eplerenone After Single and Multiple Dosing in Subjects With and Without Renal Impairment. The Journal of Clinical Pharmacology. 45(7). 810–821. 37 indexed citations
18.
Delyani, John A., Ricardo Rocha, Chyung S. Cook, et al.. (2001). Eplerenone: A Selective Aldosterone Receptor Antagonist (SARA). Cardiovascular Drug Reviews. 19(3). 185–200. 93 indexed citations
19.
Krista, L. M., et al.. (1992). Pharmacokinetics and intramuscular bioavailability of amikacin in chickens following single and multiple dosing. Journal of Veterinary Pharmacology and Therapeutics. 15(2). 133–142. 8 indexed citations
20.
Pedersoli, W. Μ., William R. Ravis, L. M. Krista, et al.. (1989). Pharmacokinetics of single doses of gentamicin given intravenously and intramuscularly to turkeys. Journal of Veterinary Pharmacology and Therapeutics. 12(2). 124–132. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Arzu Gunes Breakdown of academic impact, for papers by David W. J. Clark Breakdown of academic impact, for papers by Karin Kramer Nielsen Breakdown of academic impact, for papers by Scott R. Hamann Breakdown of academic impact, for papers by Jesús Novalbos Breakdown of academic impact, for papers by İhsan Kara Breakdown of academic impact, for papers by Pablo Zubiaur Breakdown of academic impact, for papers by Leah M. Hesse Breakdown of academic impact, for papers by Allen A. Lai Breakdown of academic impact, for papers by P d'Athis
Rankless by CCL
2026